Vertex Pharmaceuticals Incorporated (VRTX) Presents at forty fourth Annual J.P. Morgan Healthcare Conference Transcript

Jessica Fye
JPMorgan Chase & Co, Research Division

Great. Welcome, everyone. My name is Jess Fye, biotech analyst at JPMorgan, and we’re delighted to be continuing the 44th Annual JPMorgan Healthcare Conference today with Vertex.

You’re going to hear a presentation from the management team and then we’re going to go into some Q&A. So if you’re in the room here, just raise your hands, someone will bring you a microphone or if you’re listening at home, you can submit a question to the portal, and I can read it up, up here on stage.

So with that, let me pass it over to Vertex’ CEO, Reshma Kewalramani.

Reshma Kewalramani
CEO, President & Director

Thanks, Jess, and thank you to JPMorgan for hosting us. We’re at a slightly different time and a slightly different venue for those of you who come every year and it’s very good to see you all.

In the event, I’m not the first to wish you a happy New Year. Let me be amongst the first on behalf of the entire Vertex team, we’re really happy to be here, and we look forward to kicking off the year with all of you as always.

Before getting into the presentation, let me put up our safe harbor statement that you may or may not be able to read, I will be making forward-looking comments, and I encourage you to read our